Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9256 |
Name | colorectal cancer |
Definition | A large intestine cancer that is located_in the colon and/or located_in the rectum. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00063141 | Phase III | Irinotecan Cetuximab + Irinotecan | Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer | Completed | USA | SWE | SVK | NOR | NLD | ITA | GBR | FRA | FIN | DEU | CHE | BEL | AUT | AUS | 3 |
NCT00433927 | Phase III | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | Unknown status | DEU | 0 |
NCT00442637 | Phase III | Bevacizumab + Capecitabine | Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma (CAIRO3) | Unknown status | NLD | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00730158 | Phase II | Irinotecan YIV-906 | A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT00940316 | Phase II | Irinotecan Erlotinib + Panitumumab | Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | Completed | USA | 0 |
NCT00940381 | Phase I | Cetuximab + Sirolimus | Sirolimus and Cetuximab in Advanced Malignancies | Completed | USA | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT01006369 | Phase II | Hydroxychloroquine Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01037790 | Phase II | Palbociclib | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | Completed | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01260415 | Phase II | Panitumumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin | A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases | Completed | CAN | 0 |
NCT01294826 | Phase I | Cetuximab + Luminespib | Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01312857 | Phase II | Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer | Completed | USA | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | POL | ESP | 0 |
NCT01340300 | Phase II | Metformin | Exercise and Metformin in Colorectal and Breast Cancer Survivors | Completed | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Completed | USA | NLD | ITA | FRA | ESP | DEU | CAN | 0 |
NCT01358331 | Phase I | MK-8353 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | Terminated | 0 | |
NCT01436656 | Phase I | Encorafenib | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Completed | USA | NOR | FRA | ESP | CHE | AUS | 1 |
NCT01531595 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Capecitabine + Irinotecan | Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer | Recruiting | FIN | 0 |
NCT01543698 | Phase Ib/II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | CHE | CAN | BEL | AUS | 1 |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01569984 | Phase II | Bevacizumab | Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis | Completed | CAN | 0 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | NLD | GBR | FRA | ESP | AUS | 1 |
NCT01591421 | Phase Ib/II | Buparlisib + Panitumumab | P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer. | Completed | CAN | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01607957 | Phase III | Trifluridine-tipiracil hydrochloride | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE) | Completed | USA | SWE | ITA | IRL | GBR | FRA | ESP | DEU | CZE | BEL | AUT | AUS | 1 |
NCT01661972 | Phase Ib/II | Aflibercept + Capecitabine | Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01669720 | Phase II | Aflibercept | Adjuvant Aflibercept for Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01676714 | Phase II | Dovitinib | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | Completed | USA | 0 |
NCT01703390 | Phase II | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Biomarker Directed Treatment in Metastatic Colorectal Cancer | Completed | AUT | 0 |
NCT01719380 | Phase Ib/II | Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | NOR | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT01722162 | Phase II | Bevacizumab + Capecitabine | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | Completed | USA | 0 |
NCT01729923 | Phase II | Capecitabine Celecoxib | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01750918 | Phase II | Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | Completed | USA | NLD | ITA | GBR | FRA | ESP | BEL | 1 |
NCT01765582 | Phase II | Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01776307 | Phase II | Cetuximab + Napabucasin Capecitabine + Napabucasin Napabucasin + Panitumumab | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | Completed | USA | 0 |
NCT01792934 | Capecitabine + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (ORCHESTRA) | Recruiting | NLD | GBR | 0 | |
NCT01871311 | Phase I | Cetuximab + Nilotinib | A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab | Terminated | USA | 0 |
NCT01874860 | Phase I | Doxycycline | Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients | Completed | USA | 0 |
NCT01876511 | Phase II | Pembrolizumab | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | Completed | USA | 0 |
NCT01888965 | Phase II | Dovitinib | Maintenance Dovitinib for Colorectal and Pancreas Cancer | Terminated | USA | 0 |
NCT01923337 | Phase I | Alisertib + Irinotecan | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | Completed | USA | 0 |
NCT01927341 | Phase Ib/II | Binimetinib Panitumumab | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | Completed | USA | NLD | ITA | FRA | ESP | CAN | BEL | 0 |
NCT01937715 | Phase II | Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | Terminated | USA | ESP | CAN | 0 |
NCT01939223 | Phase III | Regorafenib | COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) | Terminated | USA | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 3 |
NCT01952730 | Phase I | GVAX colorectal cancer vaccine | GVAX for Colorectal Cancer | Terminated | USA | 0 |
NCT01960023 | Phase Ib/II | Cetuximab + Neratinib | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | AUS | 2 |
NCT02004106 | Phase I | Cergutuzumab amunaleukin | A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | Completed | USA | NLD | GBR | FRA | FIN | ESP | DNK | CHE | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02025803 | Phase I | Capecitabine + TAS-114 | A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02038699 | Phase Ib/II | ONC201 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT02041481 | Phase I | Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02060188 | Phase Ib/II | Nivolumab Ipilimumab | A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) | Completed | USA | ITA | IRL | FRA | ESP | CAN | BEL | AUS | 0 |
NCT02083653 | Phase II | SYM004 Fluorouracil Capecitabine | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | Completed | USA | POL | ITA | HUN | FRA | ESP | DEU | BEL | AUT | 1 |
NCT02110082 | Phase I | Cetuximab + Urelumab | Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | Completed | USA | 0 |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02124148 | Phase I | Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02141295 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin RO5520985 Bevacizumab + Fluorouracil + Leucovorin Fluorouracil + Leucovorin + RO5520985 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) | Terminated | USA | GBR | FRA | ESP | BEL | AUT | AUS | 0 |
NCT02162563 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5) | Recruiting | NLD | BEL | 0 |
NCT02168777 | Phase Ib/II | Refametinib + Regorafenib Refametinib | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer | Terminated | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02199223 | Phase I | Panitumumab + Regorafenib | Regorafenib + Panitumumab | Terminated | USA | 0 |
NCT02205398 | Phase Ib/II | Capmatinib + Cetuximab | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02227667 | Phase II | Durvalumab | Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02260440 | Phase II | Azacitidine + Pembrolizumab | A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
NCT02277093 | Phase II | Pacritinib | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | Terminated | USA | 0 |
NCT02278133 | Phase Ib/II | Cetuximab + Encorafenib + LGK974 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | Completed | USA | NLD | ITA | ISR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT02287025 | FDA approved | Regorafenib | A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes? | Terminated | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Completed | 1 | |
NCT02316340 | Phase II | Vorinostat Hydroxychloroquine Regorafenib | Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | Completed | USA | 0 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02339116 | Phase III | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2) | Unknown status | ITA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02399943 | Phase II | Panitumumab + Trametinib | A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | Completed | CAN | 0 |
NCT02402036 | Phase II | Regorafenib | A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02425683 | Phase II | Regorafenib | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | Terminated | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02437071 | Phase II | Pembrolizumab | Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | Completed | USA | 0 |
NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02448810 | Phase II | Fluorouracil + Leucovorin Imalumab Panitumumab | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02460198 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | Completed | 0 | |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT02512172 | Phase I | Azacitidine + Pembrolizumab Pembrolizumab + Romidepsin Azacitidine + Pembrolizumab + Romidepsin | A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02538627 | Phase I | Seribantumab MM-151 | Phase 1 Combination Study of MM-151 and MM-121 | Terminated | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02559024 | Phase I | MEDI6469 | Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02563002 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | Completed | 0 | |
NCT02568046 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + SYM004 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | Terminated | USA | ESP | 0 |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT02573220 | Phase I | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | Withdrawn | ITA | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02576665 | Phase I | Toca FC + Vocimagene amiretrorepvec | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Completed | USA | GBR | ESP | 1 |
NCT02600949 | Phase I | Pembrolizumab | Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma | Recruiting | USA | 0 |
NCT02605044 | Phase III | Masitinib Fluorouracil + Irinotecan + Leucovorin | Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer | Terminated | GBR | FRA | 1 |
NCT02613650 | Phase I | Binimetinib + Fluorouracil + Irinotecan + Leucovorin | A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers | Completed | USA | 0 |
NCT02630420 | Phase I | Cetuximab + Savolitinib | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | Withdrawn | 0 | |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | POL | HRV | CAN | 0 |
NCT02636036 | Phase I | Enadenotucirev + Pembrolizumab | Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors | Completed | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02654639 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02671955 | Phase I | Onvatilimab | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02703571 | Phase Ib/II | Ribociclib + Trametinib | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | Terminated | USA | NLD | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02713373 | Phase Ib/II | Cetuximab + Pembrolizumab | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02713529 | Phase Ib/II | AMG 820 + Pembrolizumab | Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT02745769 | Phase I | Merestinib + Ramucirumab Abemaciclib + Ramucirumab | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | Completed | USA | GBR | FRA | 0 |
NCT02753127 | Phase III | Fluorouracil + Irinotecan + Leucovorin Napabucasin | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C) | Completed | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 5 |
NCT02754856 | Phase I | Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab | Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases. | Completed | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02785068 | Phase I | Fluorouracil + Irinotecan + Leucovorin + MM-151 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Withdrawn | 0 | |
NCT02811497 | Phase II | Azacitidine + Durvalumab | Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) | Completed | CAN | 0 |
NCT02837263 | Phase I | Pembrolizumab | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | AUS | 1 |
NCT02861300 | Phase Ib/II | Capecitabine + Telaglenastat | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02870920 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies | Completed | CAN | 0 |
NCT02873195 | Phase II | Bevacizumab + Capecitabine Atezolizumab + Bevacizumab + Capecitabine | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Completed | USA | NLD | GBR | ESP | DEU | 2 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | 2 |
NCT02906059 | Phase I | Adavosertib + Irinotecan | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02928224 | Phase III | Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) | Completed | USA | TUR | POL | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 7 |
NCT02934529 | Phase III | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) | Active, not recruiting | DEU | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CHE | CAN | AUT | 3 |
NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02959437 | Phase Ib/II | Azacitidine + Epacadostat + Pembrolizumab | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | Terminated | USA | GBR | ESP | 0 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT02961283 | Phase I | ASN003 | Study of ASN003 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT02965417 | Phase II | SYM004 | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients | Withdrawn | 0 | |
NCT02981524 | Phase II | Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab | Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02982694 | Phase II | Atezolizumab + Bevacizumab | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | Terminated | NLD | ITA | ESP | BEL | 0 |
NCT02983578 | Phase II | Danvatirsen + Durvalumab | AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02991196 | Phase I | DS-8273a + Nivolumab | Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer | Terminated | USA | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
NCT03005002 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | Completed | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03031691 | Phase I | Brontictuzumab + Trifluridine | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03035279 | Phase I | SC-006 | A Study of SC-006 in Subjects With Advanced Cancer | Terminated | USA | 0 |
NCT03050814 | Phase II | Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | Terminated | USA | 0 |
NCT03087591 | Phase I | APN401 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | GBR | 0 |
NCT03099486 | Phase II | Fluorouracil + Leucovorin + Regorafenib | Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC | Terminated | USA | 0 |
NCT03101475 | Phase II | Durvalumab + Tremelimumab | Synergism of Immunomodulation and Tumor Ablation (ILOC) | Completed | SWE | NLD | FRA | DEU | CHE | AUT | 0 |
NCT03122509 | Phase II | Durvalumab + Tremelimumab | A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | Completed | USA | 0 |
NCT03184870 | Phase Ib/II | BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | ESP | DEU | CAN | BEL | AUS | 0 |
NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
NCT03189030 | Phase I | pLADD | Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT03203525 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus | Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer | Recruiting | USA | 0 |
NCT03206073 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | Completed | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03215264 | Phase Ib/II | Entinostat + Hydroxychloroquine + Regorafenib | Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03223779 | Phase Ib/II | Trifluridine | Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | Recruiting | USA | 0 |
NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Completed | USA | ISR | AUS | 0 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Active, not recruiting | USA | 0 |
NCT03256344 | Phase I | Atezolizumab + Talimogene laherparepvec | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Completed | USA | ESP | DEU | CHE | BEL | AUS | 0 |
NCT03259867 | Phase II | Nivolumab Pembrolizumab | Combination of TATE and PD-1 Inhibitor in Liver Cancer | Recruiting | USA | 0 |
NCT03263429 | Phase Ib/II | Irinotecan + Panitumumab + Telaglenastat | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | Completed | USA | 0 |
NCT03265080 | Phase I | ADXS-NEO | Expressing Personalized Tumor Antigens Study | Terminated | USA | 0 |
NCT03271047 | Phase Ib/II | Binimetinib + Ipilimumab + Nivolumab Binimetinib + Nivolumab | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | Completed | USA | NLD | GBR | ESP | BEL | 0 |
NCT03289962 | Phase I | Autogene cevumeran Atezolizumab + Autogene cevumeran | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | SWE | NLD | GBR | ESP | DEU | CAN | BEL | 0 |
NCT03290937 | Phase I | Cetuximab + Irinotecan + Utomilumab | Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03307603 | Phase Ib/II | Nivolumab + Yttrium-90 microsphere therapy | Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer | Withdrawn | 0 | |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03340558 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) | Withdrawn | USA | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
NCT03374254 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) | Completed | USA | CAN | 0 |
NCT03391232 | Phase I | PolyPEPI1018 | Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) | Completed | USA | ITA | 0 |
NCT03403634 | Phase I | Celecoxib + Interferon alpha-2b + Rintatolimod | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | Completed | USA | 0 |
NCT03407976 | Phase Ib/II | Pembrolizumab + Rivoceranib | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Terminated | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | GBR | FRA | ESP | 0 |
NCT03414983 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) | Completed | USA | ESP | CAN | 2 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | CHE | 1 |
NCT03428126 | Phase II | Durvalumab + Trametinib | Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | Completed | USA | 0 |
NCT03428958 | Phase I | A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Completed | USA | GBR | FRA | 0 | |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03439462 | Phase Ib/II | Bevacizumab + Fluorouracil + Leucovorin + Nab-rapamycin + Oxaliplatin | ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03446157 | Phase II | Cetuximab + Palbociclib | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03457896 | Phase II | Cetuximab + Neratinib Neratinib + Trastuzumab | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | Unknown status | USA | 0 |
NCT03473925 | Phase II | Navarixin + Pembrolizumab | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | Completed | USA | ISR | CAN | AUS | 1 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT03519412 | Phase II | Pembrolizumab Temozolomide Pembrolizumab + Temozolomide | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA) | Active, not recruiting | ITA | 0 |
NCT03520946 | Phase III | Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) | Completed | DEU | 0 |
NCT03526835 | Phase I | MCLA-158 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Recruiting | USA | NLD | GBR | FRA | ESP | BEL | 0 |
NCT03530267 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Aflibercept + Fluorouracil + Leucovorin | Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (ELDERLY) | Completed | DEU | 0 |
NCT03531632 | Phase Ib/II | MGD007 + Retifanlimab | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03547999 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CV301 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | Active, not recruiting | USA | 0 |
NCT03549338 | Phase II | Modotuximab Futuximab SYM004 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | Terminated | USA | ITA | ESP | DEU | 0 |
NCT03555149 | Phase Ib/II | Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | Terminated | USA | FRA | CHE | AUS | 1 |
NCT03563157 | Phase Ib/II | Aldoxorubicin + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin + Regorafenib + Trastuzumab Regorafenib | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Terminated | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03616574 | Phase I | CA102N CA102N + Trifluridine-tipiracil hydrochloride | First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03631407 | Phase II | Pembrolizumab + Vicriviroc | Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | Completed | USA | CAN | 0 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | AUS | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Completed | USA | POL | NZL | NLD | ITA | GBR | FRA | ESP | BRA | ARG | 2 |
NCT03657641 | Phase Ib/II | Pembrolizumab + Regorafenib | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03658772 | Phase I | Grapiprant + Pembrolizumab | Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer | Completed | USA | 0 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03668431 | Phase II | Dabrafenib + Spartalizumab + Trametinib | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | Unknown status | USA | 0 |
NCT03693170 | Phase II | Binimetinib + Cetuximab + Encorafenib | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) | Completed | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUT | 1 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03714958 | Phase I | Siremadlin + Trametinib | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) | Completed | FRA | 0 |
NCT03720678 | Phase I | Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies | Completed | USA | AUS | 0 |
NCT03724071 | Phase Ib/II | Flucytosine + TG6002 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | Terminated | FRA | ESP | BEL | 0 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Completed | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03785210 | Phase II | Nivolumab + Tadalafil + Vancomycin | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | Completed | USA | 0 |
NCT03791398 | Phase Ib/II | Nivolumab + ONC201 | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379) | Terminated | USA | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03795311 | Phase Ib/II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) (FOLFIRINOX3) | Active, not recruiting | FRA | 0 |
NCT03796884 | Phase II | Linaclotide | Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
NCT03798626 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | Active, not recruiting | USA | ITA | ISR | GBR | ESP | DEU | CZE | CAN | BEL | AUS | 5 |
NCT03802747 | Phase I | Durvalumab + Tremelimumab Durvalumab | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Withdrawn | 0 | |
NCT03819387 | Phase I | NBF-006 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | Completed | USA | 0 |
NCT03829462 | Phase III | Regorafenib Irinotecan + Regorafenib | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) | Active, not recruiting | FRA | 0 |
NCT03844620 | Phase II | Regorafenib Trifluridine-tipiracil hydrochloride Regorafenib + Trifluridine-tipiracil hydrochloride | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03844750 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab | Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | Recruiting | USA | 0 |
NCT03851614 | Phase II | Cediranib + Durvalumab Durvalumab + Olaparib | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | Active, not recruiting | CAN | 0 |
NCT03865082 | Phase II | IMO-2125 + Ipilimumab + Nivolumab | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Active, not recruiting | USA | 0 |
NCT03871959 | Phase I | Pembrolizumab + Xevinapant | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) | Completed | FRA | 0 |
NCT03875313 | Phase Ib/II | Talazoparib + Telaglenastat | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
NCT03879811 | Phase II | Nivolumab Temozolomide | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer | Withdrawn | 0 | |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | ESP | DEU | 3 |
NCT03900442 | Phase I | GGTI-2418 | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies | Unknown status | AUS | 0 |
NCT03929666 | Phase II | Cisplatin + Gemcitabine Cisplatin + Fluorouracil + ZW25 Capecitabine + Oxaliplatin + ZW25 Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | AUS | 0 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
NCT03965845 | Phase Ib/II | Palbociclib + Telaglenastat | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | Completed | USA | 0 |
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
NCT03981614 | Phase II | Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | Completed | USA | 0 |
NCT03983993 | Phase II | Niraparib + Panitumumab | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect) | Active, not recruiting | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT04000529 | Phase I | Spartalizumab + TNO155 Ribociclib + TNO155 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Terminated | USA | ESP | DEU | BEL | AUS | 4 |
NCT04008030 | Phase III | Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) | Recruiting | USA | TUR | ROU | NOR | NLD | ITA | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT04008797 | Phase I | Lenvatinib E7386 + Lenvatinib | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | USA | FRA | 3 |
NCT04034459 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) | Active, not recruiting | DEU | 0 |
NCT04041310 | Phase I | GAd-209-FSP + MVA-209-FSP | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Active, not recruiting | USA | ITA | GBR | ESP | CAN | BEL | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04046445 | Phase Ib/II | ATP128 + Ezabenlimab ATP128 ATP128 + Ezabenlimab + VSV-GP128 | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01) | Active, not recruiting | USA | DEU | CHE | BEL | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04069026 | Phase I | BAY2416964 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | Completed | USA | GBR | ESP | DEU | CAN | 0 |
NCT04072198 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR) | Unknown status | ITA | 0 |
NCT04073615 | Phase Ib/II | Rivoceranib + Trifluridine-tipiracil hydrochloride Rivoceranib Trifluridine-tipiracil hydrochloride | Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT04083599 | Phase Ib/II | GEN1042 | GEN1042 Safety Trial in Subjects With Malignant Solid Tumors | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | 4 |
NCT04096417 | Phase II | Pemigatinib | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | Active, not recruiting | USA | 0 |
NCT04108481 | Phase Ib/II | Durvalumab | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) | Suspended | USA | 0 |
NCT04117087 | Phase I | Ipilimumab + Nivolumab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |
NCT04130516 | Phase Ib/II | LNS8801 LNS8801 + Pembrolizumab | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Recruiting | USA | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04145193 | Phase II | Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | Withdrawn | 0 | |
NCT04164069 | Phase I | Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin | Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab | Active, not recruiting | USA | 0 |
NCT04166383 | Phase II | Nivolumab + VB-111 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Completed | USA | 0 |
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Terminated | USA | 0 |
NCT04185883 | Phase Ib/II | Fluorouracil + Irinotecan + Panitumumab + Sotorasib AMG 404 + Sotorasib Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sotorasib Sotorasib + TNO155 Atezolizumab + Sotorasib Pembrolizumab + Sotorasib Sotorasib Everolimus + Sotorasib Bevacizumab-awwb + Fluorouracil + Oxaliplatin + Sotorasib Bevacizumab-awwb + Fluorouracil + Irinotecan + Sotorasib BI 1701963 + Sotorasib Palbociclib + Sotorasib Afatinib + Sotorasib RMC-4630 + Sotorasib Panitumumab + Sotorasib + Trametinib | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | Recruiting | USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS | 3 |
NCT04189055 | Phase II | Cetuximab + Irinotecan Cetuximab | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) | Recruiting | FRA | 0 |
NCT04194034 | Phase Ib/II | Flucytosine + TG6002 | Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer | Terminated | GBR | FRA | 0 |
NCT04244552 | Phase I | ATRC-101 | First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Terminated | USA | 0 |
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | AUS | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04256707 | Phase Ib/II | Pembrolizumab + Selinexor Docetaxel + Selinexor Fluorouracil + Irinotecan + Leucovorin + Selinexor Selinexor | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT) | Recruiting | ISR | 0 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Completed | USA | GBR | ESP | DEU | 1 |
NCT04270864 | Phase I | IMO-2125 + Ipilimumab + Nivolumab | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) | Terminated | FRA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) | Terminated | USA | CAN | 1 |
NCT04330664 | Phase Ib/II | Adagrasib + TNO155 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Active, not recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | DNK | 3 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | POL | LVA | LTU | HRV | CHE | BRA | 2 |
NCT04421820 | Phase I | BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Recruiting | USA | IRL | CAN | 1 |
NCT04425239 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE) | Completed | ITA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Active, not recruiting | USA | 1 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Active, not recruiting | USA | FRA | 0 |
NCT04449874 | Phase I | Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Recruiting | USA | POL | NZL | NOR | NLD | ITA | ISR | HUN | GBR | ESP | DEU | CHE | CAN | BRA | BEL | AUS | 3 |
NCT04450836 | Phase II | Regorafenib + Trifluridine-tipiracil hydrochloride | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) | Active, not recruiting | FRA | BEL | 0 |
NCT04468607 | Phase I | BLYG8824A | A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer | Active, not recruiting | USA | ESP | AUS | 0 |
NCT04488003 | Phase II | Ulixertinib | Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | Terminated | USA | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Completed | USA | 0 |
NCT04508140 | Phase II | BO-112 + Pembrolizumab | Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis | Terminated | ITA | ESP | BEL | 0 |
NCT04511039 | Phase I | Talazoparib + Trifluridine-tipiracil hydrochloride | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT04513951 | Phase II | Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) | Active, not recruiting | ITA | 0 |
NCT04515394 | Phase II | Cetuximab + Tepotinib | Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | Terminated | USA | ITA | GBR | FRA | ESP | CZE | BEL | 1 |
NCT04534218 | Phase II | Aspirin + Capecitabine + Cyclophosphamide + Regorafenib | Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer (REPROGRAM-01) | Completed | FRA | 0 |
NCT04535401 | Phase I | Elimusertib + Fluorouracil + Irinotecan + Leucovorin | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | Active, not recruiting | USA | 0 |
NCT04564898 | Phase Ib/II | Bevacizumab + Capecitabine + Trifluridine-tipiracil hydrochloride | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (TriComB) | Active, not recruiting | ITA | 0 |
NCT04585035 | Phase Ib/II | D-1553 | Study to Evaluate D-1553 in Subjects With Solid Tumors | Active, not recruiting | USA | AUS | 2 |
NCT04587128 | Phase II | Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | Recruiting | USA | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04595266 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + unspecified EGFR antibody Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + unspecified EGFR antibody | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL) | Recruiting | ESP | 0 |
NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04607421 | Phase III | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Active, not recruiting | USA | SWE | SVK | POL | NZL | NOR | NLD | ITA | GBR | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 9 |
NCT04609579 | Phase I | SNX281 Pembrolizumab + SNX281 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Terminated | USA | 0 |
NCT04616196 | Phase Ib/II | Cetuximab + NKTR-255 | A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Completed | USA | 0 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Completed | USA | ITA | ESP | 0 |
NCT04645797 | Phase I | APR003 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions | Completed | USA | 0 |
NCT04659382 | Phase II | Atezolizumab + Bevacizumab + Capecitabine + Oxaliplatin | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) | Recruiting | FRA | 0 |
NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Terminated | USA | CAN | 0 |
NCT04701476 | Phase II | Pembrolizumab + Tirapazamine | TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Recruiting | USA | 1 |
NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
NCT04705818 | Phase II | Durvalumab + Tazemetostat | Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) | Recruiting | FRA | 0 |
NCT04708470 | Phase Ib/II | Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | Recruiting | USA | 0 |
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Completed | AUS | 0 |
NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Suspended | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04761614 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Riluzole | Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04776655 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) | Unknown status | ITA | 0 |
NCT04787341 | Phase II | Regorafenib Panitumumab | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) | Recruiting | ITA | 0 |
NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Active, not recruiting | FRA | 0 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04808362 | Phase Ib/II | OMO-103 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) | Terminated | ESP | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Recruiting | CAN | 0 |
NCT04837196 | Phase Ib/II | ASP7517 + Pembrolizumab ASP7517 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Completed | USA | 0 |
NCT04844073 | Phase Ib/II | MVC-101 | A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer | Recruiting | USA | GBR | AUS | 1 |
NCT04854434 | Phase II | Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | Terminated | USA | 0 |
NCT04870034 | Phase I | Binimetinib + Palbociclib | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | Withdrawn | USA | 0 |
NCT04874207 | FDA approved | Regorafenib | Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib (RePERSO) | Active, not recruiting | FRA | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) | Active, not recruiting | USA | TUR | ROU | POL | NLD | LTU | ITA | HUN | GRC | GBR | FRA | EST | ESP | DNK | DEU | CAN | BEL | 5 |
NCT04903873 | Phase Ib/II | EU101 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04907539 | Phase II | Denosumab + Nivolumab + RXC004 Denosumab + RXC004 | A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) | Completed | USA | GBR | ESP | 1 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab-tpzi | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Completed | AUS | 1 |
NCT04916236 | Phase I | LY3214996 + RMC-4630 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) | Unknown status | NLD | 0 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | NZL | NLD | ISR | FRA | ESP | BEL | AUS | 2 |
NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUT | 0 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ISR | ESP | 0 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05007132 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | Recruiting | DEU | 0 |
NCT05029882 | Phase I | ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | Recruiting | USA | POL | ISR | FRA | ESP | AUS | 4 |
NCT05039177 | Phase Ib/II | Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) | Active, not recruiting | USA | 0 |
NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Active, not recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05061017 | Phase II | Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | Completed | USA | 0 |
NCT05061537 | Phase I | PF-06801591 + PF-07263689 PF-07263689 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Terminated | USA | 0 |
NCT05062317 | Phase II | Capecitabine Leucovorin Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | Recruiting | USA | 0 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | ESP | DNK | CHE | CAN | AUS | 7 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Terminated | USA | 0 |
NCT05076552 | Phase I | TACH101 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | Active, not recruiting | USA | 0 |
NCT05084859 | Phase I | Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | Terminated | USA | AUS | 0 |
NCT05086692 | Phase Ib/II | MDNA11 + Pembrolizumab | A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) | Recruiting | USA | CAN | AUS | 1 |
NCT05091346 | Phase Ib/II | E7386 + Pembrolizumab | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Completed | USA | GBR | ESP | 1 |
NCT05091528 | Phase Ib/II | SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | Terminated | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Terminated | USA | 0 |
NCT05104567 | Phase II | Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | Terminated | USA | NLD | ITA | FRA | ESP | BEL | 3 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05116891 | Phase Ib/II | Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | Completed | FRA | ESP | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Terminated | USA | 0 |
NCT05141721 | Phase II | Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05167409 | Phase II | Cetuximab + Evorpacept + Pembrolizumab | A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05176665 | Phase Ib/II | EMB-01 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Recruiting | USA | 1 |
NCT05185947 | Phase II | Nilotinib + Paclitaxel | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer | Active, not recruiting | USA | 0 |
NCT05201352 | Phase Ib/II | Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride + XB2001 | Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1alpha True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN) | Recruiting | FRA | 0 |
NCT05201612 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA) | Recruiting | ESP | 0 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | SVK | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 4 |
NCT05238558 | Phase I | FMPV-1 + Sargramostim | Safety and Immune Response to FMPV-1 | Completed | GBR | 0 |
NCT05243862 | Phase II | Atezolizumab + PolyPEPI1018 | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | Active, not recruiting | USA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05259696 | Phase Ib/II | E-602 E-602 + Pembrolizumab | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) | Active, not recruiting | USA | 0 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 | |
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | AUS | 3 |
NCT05307874 | Phase Ib/II | Aldesleukin + ICT01 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) | Recruiting | FRA | 0 |
NCT05319314 | Phase I | GCC19CART | GCC19CART for Patients With Metastatic Colorectal Cancer (CARAPIA-1) | Recruiting | USA | 0 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05350501 | Phase II | EO2040 + Nivolumab | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (CLAUDE) | Completed | USA | 0 |
NCT05358249 | Phase Ib/II | JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 2 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05360680 | Phase I | CUE-102 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05397171 | Phase Ib/II | AZD8853 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | Terminated | USA | CAN | 0 |
NCT05411133 | Phase I | ARB202 + Atezolizumab ARB202 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | Recruiting | AUS | 1 |
NCT05427487 | Phase I | IVX037 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |
NCT05446129 | Phase I | Effi-DEM + Pembrolizumab Effi-DEM + Ezabenlimab | A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery | Terminated | USA | 0 |
NCT05451849 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-510 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | 0 |
NCT05453825 | Phase II | Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05462236 | Phase II | ETC-1907206 ETC-1907206 + Irinotecan ETC-1907206 + Pembrolizumab | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | Recruiting | AUS | 0 |
NCT05462613 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02) | Recruiting | FRA | 0 |
NCT05464030 | Phase I | M9140 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors | Recruiting | USA | ESP | CAN | 2 |
NCT05480306 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin | Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) | Active, not recruiting | USA | DEU | 1 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Active, not recruiting | USA | AUS | 0 |
NCT05513742 | Phase II | CTX-009 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT05518032 | Phase II | Pembrolizumab | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | Withdrawn | USA | 0 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | AUS | 0 |
NCT05544929 | Phase I | KFA115 KFA115 + Pembrolizumab | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Recruiting | USA | GBR | FRA | DEU | CHE | CAN | 0 |
NCT05572684 | Phase Ib/II | NC410 + Pembrolizumab | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05573035 | Phase I | LYL845 | A Study to Investigate LYL845 in Adults With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05576896 | Phase II | Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | Recruiting | USA | 0 |
NCT05578092 | Phase Ib/II | Adagrasib + MRTX0902 MRTX0902 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Recruiting | USA | 1 |
NCT05584709 | Phase I | STI-6129 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05585320 | Phase Ib/II | IMM-1-104 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05593328 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | Active, not recruiting | USA | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05605509 | Phase II | Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 | RP-6306 in Patients With Advanced Cancer | Recruiting | CAN | 0 |
NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Recruiting | USA | AUS | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05619172 | Phase II | Cetuximab + SOT101 | A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer | Terminated | FRA | ESP | BEL | 0 |
NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Recruiting | USA | 1 |
NCT05636215 | Phase Ib/II | IBI354 | A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Terminated | USA | 1 |
NCT05650203 | Phase I | JS006 + JS009 + Toripalimab-tpzi JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05668585 | Phase Ib/II | Cetuximab + CFT1946 CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05674526 | Phase I | Cetuximab + WU-NK-101 | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | Recruiting | USA | 0 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05688280 | Phase Ib/II | IP-001 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) | Recruiting | USA | GBR | FRA | DEU | CHE | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT05694936 | Phase II | Cetuximab + Panitumumab Cetuximab + Panitumumab + Valproic acid | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | Recruiting | AUS | 0 |
NCT05714553 | Phase Ib/II | Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05725200 | Phase II | Dasatinib Palbociclib Gemcitabine Trastuzumab Cetuximab Pertuzumab Panobinostat Alectinib Venetoclax Larotrectinib Encorafenib Everolimus Idelalisib Crizotinib Pembrolizumab Methotrexate Talazoparib | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer (EVIDENT) | Recruiting | NOR | 0 |
NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05731947 | Phase Ib/II | Revumenib | Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT05733000 | Phase II | CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Recruiting | USA | 0 |
NCT05736731 | Phase Ib/II | A2B530 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) | Recruiting | USA | 0 |
NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05759728 | Phase Ib/II | CNA3103 | A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | Recruiting | AUS | 0 |
NCT05759923 | Phase I | OATD-02 | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours | Recruiting | POL | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Terminated | USA | 0 |
NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05789069 | Phase I | HFB200603 HFB200603 + Tislelizumab | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT05800964 | Phase I | AMG 305 | Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. | Recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 2 |
NCT05803382 | Phase I | Capecitabine + ZEN-3694 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | Recruiting | USA | 0 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | BEL | 0 |
NCT05830097 | Phase Ib/II | CBP-1019 | A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT05843188 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hydroxychloroquine + Irinotecan + Leucovorin | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | Recruiting | CAN | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT05892068 | Phase II | Tucatinib | A Study of Tucatinib Given Before Surgery to People With HER2 positive Cancers That Have Spread to the Brain | Recruiting | USA | 0 |
NCT05900648 | Phase II | Regorafenib + XmAb20717 | Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) | Withdrawn | 0 | |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05909995 | Phase I | INCB099280 + Ipilimumab | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors | Active, not recruiting | USA | CAN | 1 |
NCT05919264 | Phase Ib/II | FOG-001 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05948865 | Phase I | CPO301 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | CAN | 0 |
NCT05957367 | Phase Ib/II | DCC-3116 + Ripretinib Cetuximab + DCC-3116 + Encorafenib | A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Recruiting | USA | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05983133 | Phase I | SGN-EGFRd2 | A Study of SGN-EGFRd2 in Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05983367 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | Active, not recruiting | FRA | ESP | BEL | 0 |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05989724 | Phase I | SON-DP | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06003998 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab (INTERACT-II) | Recruiting | NLD | 0 |
NCT06006923 | Phase II | Pembrolizumab Pembrolizumab + Regorafenib | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | Recruiting | USA | 0 |
NCT06012734 | Phase I | Atezolizumab + LB-100 | LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (CoLBAt) | Recruiting | NLD | 0 |
NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06024174 | Phase Ib/II | Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 | A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors | Terminated | USA | ISR | FRA | FIN | AUS | 0 |
NCT06026410 | Phase I | Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) | Recruiting | USA | 0 |
NCT06039384 | Phase I | Adagrasib + INCB099280 | A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Active, not recruiting | USA | ITA | GBR | ESP | 0 |
NCT06047379 | Phase Ib/II | NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Recruiting | USA | 0 |
NCT06051695 | Phase Ib/II | A2B694 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) | Recruiting | USA | 0 |
NCT06052852 | Phase Ib/II | BDC-3042 + Pembrolizumab BDC-3042 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Not yet recruiting | FRA | 0 |
NCT06106308 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Recruiting | USA | 0 |
NCT06107413 | Phase II | ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Recruiting | USA | ISR | ESP | BEL | 3 |
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06129604 | Phase II | TPST-1495 | Pilot Window of Opportunity Trial (POET) | Recruiting | USA | 0 |
NCT06131398 | Phase I | AMG 355 + Pembrolizumab AMG 355 | A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Recruiting | USA | POL | NLD | FRA | ESP | CHE | CAN | AUS | 3 |
NCT06131840 | Phase I | SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | ESP | CAN | 0 |
NCT06149481 | Phase Ib/II | ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept + Retifanlimab + SX-682 ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept + Retifanlimab | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | Recruiting | USA | 0 |
NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
NCT06171178 | Phase I | ASP1012 + Pembrolizumab ASP1012 | A Study of ASP1012 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06179160 | Phase I | Cetuximab + INCB161734 + Retifanlimab INCB161734 | A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | AUS | 1 |
NCT06194877 | Phase I | BGB3245 + Panitumumab | A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers | Recruiting | USA | AUS | 0 |
NCT06205836 | Phase II | Cemiplimab Cemiplimab + Fianlimab | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | Recruiting | USA | 0 |
NCT06239467 | Phase I | OKI-219 + Trastuzumab OKI-219 Fulvestrant + OKI-219 | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01) | Recruiting | USA | ITA | FRA | ESP | BEL | 1 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | AUS | 0 |
NCT06243393 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Metastatic Colorectal Cancer (TROPHIT1) | Recruiting | DEU | 0 |
NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
NCT06268015 | Phase II | Balstilimab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Balstilimab + Botensilimab Balstilimab + Bevacizumab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin | Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo) | Recruiting | USA | 0 |
NCT06270082 | Phase I | IK-595 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06305247 | Phase Ib/II | IPN01194 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Recruiting | USA | FRA | ESP | 0 |
NCT06307249 | Phase I | Bevacizumab + Palbociclib | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA (PTST_PALBEVA) | Recruiting | LBN | 0 |
NCT06328738 | Phase I | ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | Recruiting | USA | NLD | ITA | FRA | ESP | BEL | 1 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06331598 | Phase II | Atezolizumab Atezolizumab + Tiragolumab | A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) | Recruiting | ESP | 0 |
NCT06332274 | Phase III | Tislelizumab | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA) | Not yet recruiting | FRA | 0 |
NCT06336902 | Phase I | Balstilimab + Botensilimab + Vitamin C | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Not yet recruiting | USA | 0 |
NCT06343402 | Phase I | BBO-8520 BBO-8520 + Pembrolizumab | Study of BBO-8520 in Adult Subjects with KRASG12C Non-small Cell Lung and Colorectal Cancer | Recruiting | USA | AUS | 0 |
NCT06358430 | Phase I | Cyclophosphamide + Fludarabine Cetuximab + TROP2-CAR/IL15-transduced CBNK cells | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | Not yet recruiting | USA | 0 |
NCT06362369 | Phase Ib/II | 7HP349 + Ipilimumab + Nivolumab | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Recruiting | USA | 0 |
NCT06365970 | Phase II | Dostarlimab-gxly + Niraparib | Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers | Not yet recruiting | USA | 0 |
NCT06369259 | Phase II | Cetuximab + Defactinib + RO5126766 | Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer | Not yet recruiting | USA | 0 |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06400472 | Phase I | LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 2 |
NCT06400485 | Phase I | AMT-676 | AMT-676 in Patients With Advanced Solid Tumors | Recruiting | AUS | 1 |
NCT06410534 | Phase II | Nivolumab Ipilimumab + Nivolumab | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT06411600 | Phase II | Bevacizumab + Cetuximab + Encorafenib Bevacizumab | Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE) | Recruiting | ESP | 0 |
NCT06412198 | Phase Ib/II | Adagrasib + Cemiplimab + Cetuximab | A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations | Recruiting | USA | 0 |
NCT06416436 | Phase I | Atezolizumab | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | Not yet recruiting | USA | 0 |
NCT06425133 | Phase II | Regorafenib Aspirin + Capecitabine + Cyclophosphamide + Regorafenib | Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers (CARE) | Not yet recruiting | FRA | 0 |
NCT06428409 | Phase Ib/II | Fluorouracil + Leucovorin + SKB264 SKB264 | A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) | Recruiting | USA | ITA | GBR | ESP | CHE | CAN | AUS | 5 |
NCT06447662 | Phase I | PF-07934040 Gemcitabine + Nab-paclitaxel + PF-07934040 Carboplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 Pembrolizumab + PF-07934040 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + PF-07934040 Cetuximab + PF-07934040 Cisplatin + Pembrolizumab + Pemetrexed Disodium + PF-07934040 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Recruiting | USA | 1 |
NCT06448364 | Phase I | PF-06801591 + PF-07329640 PF-07329640 Bevacizumab + PF-07329640 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR) | Terminated | USA | 1 |
NCT06451497 | Phase I | ZM008 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06475937 | Phase I | DM001 | A Study of DM001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06490536 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin Ipilimumab + Nivolumab Irinotecan + Temozolomide Fluorouracil + Leucovorin Capecitabine Fluorouracil + Irinotecan + Leucovorin Fluorouracil Capecitabine + Oxaliplatin | The Sagittarius Trial | Recruiting | ITA | ESP | 0 |
NCT06509126 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE-2) | Recruiting | ITA | 0 |
NCT06509906 | Phase I | HRS-1167 + Irinotecan Bevacizumab + Fluorouracil + HRS-1167 + Irinotecan + Leucovorin | M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) | Recruiting | USA | ESP | AUS | 2 |
NCT06522919 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Pembrolizumab | Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax) | Not yet recruiting | ITA | 0 |
NCT06544655 | Phase I | BMS-986484 + Nivolumab BMS-986484 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06546553 | Phase I | PF-07826390 PF-06801591 + PF-07826390 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. | Recruiting | USA | 0 |
NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT06553885 | Phase II | Enfortumab vedotin-ejfv | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | Not yet recruiting | USA | 0 |
NCT06576037 | Phase I | CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Recruiting | USA | 0 |
NCT06580938 | Phase I | PF-07921585 PF-06801591 + PF-07921585 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | Recruiting | USA | 0 |
NCT06596694 | Phase Ib/II | Patritumab deruxtecan | Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) | Recruiting | USA | ISR | AUS | 2 |
NCT06598007 | Phase Ib/II | CT3001 | A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06599502 | Phase Ib/II | AZD0022 + Cetuximab AZD0022 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01) | Recruiting | USA | TUR | POL | NLD | ITA | ESP | CAN | BEL | AUS | 0 |
NCT06603818 | Phase II | Atezolizumab + Tiragolumab | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) | Not yet recruiting | USA | 0 |
NCT06614192 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride ABBV-400 | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | Recruiting | USA | ISR | 2 |
NCT06625775 | Phase I | BBO-10203 + Trastuzumab BBO-10203 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Recruiting | USA | 0 |
NCT06626256 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + STIL101 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | Not yet recruiting | USA | 0 |
NCT06630624 | Phase Ib/II | IP-001 | Dose Finding, Efficacy and Immunological Response of IP-001 Following RFA, MWA or IRE for CRLM (INJECTABL-II) | Recruiting | NLD | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |
NCT06651593 | Phase II | BND-22 + Cemiplimab | Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | Not yet recruiting | USA | 0 |
NCT06663839 | Phase I | NILK-2301 | A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer | Recruiting | ESP | 0 |
NCT06680739 | Phase II | Durvalumab Durvalumab + Tremelimumab | Single cEll pRofiling PErsistaNce To ImmuNothErapy (SERPENTINE) | Recruiting | ESP | 0 |
NCT06697197 | Phase Ib/II | BMS-986482 + Nivolumab and relatlimab-rmbw Bevacizumab + BMS-986482 BMS-986482 BMS-986298 + BMS-986482 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT06710847 | Phase Ib/II | GSK4418959 GSK4418959 + unspecified PD-1 antibody | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (SYLVER) | Not yet recruiting | USA | NLD | AUS | 1 |